Does Anthem Cover Weight Loss Medication? Employer, Medicaid, and Medicare

Anthem does not cover weight loss medications under most of its plans. Across commercial, Medicare Advantage, and most Medicaid managed care coverage, drugs like Wegovy, Zepbound, and Saxenda are excluded when prescribed solely for weight loss. Narrow exceptions exist for specific medical conditions, some state Medicaid programs, and a new federal Medicare demonstration launching in mid-2026.

Employer and Individual Market Plans

If you have Anthem coverage through an employer or the individual market, your pharmacy benefit is run by CarelonRx. Anthem’s provider communications state that member benefits “specifically exclude weight loss drugs” for most enrollees. ¹ GLP-1 receptor agonists — the class that includes Wegovy, Ozempic, and Zepbound — are generally approved only for type 2 diabetes, not weight management.

State-level details illustrate how firm the line is. In California, Anthem reclassified all GLP-1 drugs from Tier 3 to Tier 4 (specialty) status on January 1, 2025, and treats them as non-formulary. Claims have been denied as exclusions since roughly October 2024. In Nevada, Anthem Blue Cross Blue Shield does not cover GLP-1 medications for weight loss under large group fully insured plans, and even the diabetes approvals require prior authorization and step therapy with a documented metformin trial. ²

One caveat matters here. Employer-sponsored plans set their own benefit designs, and some employers choose to add weight loss drug coverage even when Anthem’s default formulary excludes it. CarelonRx has acknowledged that employers are weighing member interest in GLP-1s against long-term cost and utilization concerns. ³ Check your specific plan documents or call the number on your insurance card to confirm what your employer has elected.

Medicaid Managed Care

Anthem runs Medicaid managed care plans in several states, and the answer depends heavily on state policy. Two of its largest Medicaid states show the range.

California (Medi-Cal Rx)

Effective January 1, 2026, Medi-Cal Rx eliminated coverage for GLP-1 medications prescribed for weight loss. Wegovy, Zepbound, and Saxenda were removed entirely from the Contract Drugs List. Claims for these three are denied with a “Product/Service Not Covered” rejection code regardless of the prescribing indication. ⁴

Other GLP-1 drugs still on the formulary — Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, and Trulicity — are restricted to type 2 diabetes. Claims submitted without a qualifying diabetes diagnosis are rejected. ⁴

A few exceptions remain. Wegovy can be considered for prior authorization if prescribed for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) or cardiovascular disease. Zepbound can be considered if prescribed for obstructive sleep apnea. For members under 21, requests tied to weight loss are reviewed for medical necessity under the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit. ⁴

Virginia (Anthem HealthKeepers Plus)

Virginia keeps weight loss drug coverage, but the prior authorization is strict. To get Wegovy, Saxenda, or Zepbound approved for weight management, you need a BMI above 40 with no additional risk factors, or above 37 with at least one risk factor such as high cholesterol, high blood pressure, or type 2 diabetes. ⁵

You also need to have tried and failed (or be intolerant to) at least one non-GLP-1 weight loss medication, be participating in nutritional counseling and a physical activity program, and commit to a weight loss treatment plan. A “trial failure” for a GLP-1 is defined as six months without at least a 5% reduction in body weight. Initial approval runs six months. Renewals require proof of at least 5% weight loss, and coverage stops once your BMI drops below 25. ⁵

Virginia’s Department of Medical Assistance Services notes that managed care organizations may use different guidelines than the state’s fee-for-service program, so call Anthem directly for the current criteria. ⁶

Medicare Advantage

Federal law has long prohibited Medicare Part D from covering drugs prescribed solely for weight loss, and that applies to every Anthem Medicare Advantage prescription drug (MA-PD) plan. GLP-1s under these plans are approved only for a covered indication, mainly type 2 diabetes, with verification such as an A1c of 6.5% or higher. ⁷

Starting July 1, 2026, the CMS Medicare GLP-1 Bridge program gives Medicare beneficiaries, including Anthem MA-PD enrollees, access to Wegovy and Zepbound for weight loss at a $50 copay per prescription. ⁸

The Bridge runs outside Anthem’s Part D benefit entirely. Anthem does not process the claims, carry financial risk, or need to opt in. Providers submit prior authorization requests to a CMS-designated central processor (Humana), which handles approvals and pharmacy payments directly. ⁸ If a provider accidentally sends a weight loss GLP-1 request to Anthem, CMS has asked plans to redirect them.

To qualify, you must be at least 18 and meet one of these thresholds when starting therapy:

BMI of 35 or higher, with a prescription for weight reduction and lifestyle modification. No additional diagnosis required.
BMI of 30 or higher, with heart failure with preserved ejection fraction, uncontrolled hypertension despite two medications, or chronic kidney disease stage 3a or above.
BMI of 27 or higher, with pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.

Beneficiaries with type 2 diabetes, obstructive sleep apnea, or MASH are excluded from the Bridge because those conditions are already covered through standard Part D formulary processes. ⁹ The Bridge is set to run through the end of 2026 and acts as a precursor to the BALANCE Model, a longer-term voluntary program Part D sponsors can join starting January 2027. ¹⁰

Medical Conditions That Can Unlock Coverage

Even where weight loss alone is excluded, a GLP-1 may still be covered when the prescribing indication is a different qualifying condition. The practical paths are:

Type 2 diabetes, which remains the main approved use across commercial, Medicaid, and Medicare Advantage plans.
Cardiovascular disease, which can trigger Wegovy coverage under California Medi-Cal Rx prior authorization and matters for the Medicare Bridge program.
Noncirrhotic MASH, a possible Wegovy indication under Medi-Cal Rx.
Obstructive sleep apnea, a possible Zepbound indication under Medi-Cal Rx.

If you have an established cardiovascular diagnosis, framing the prescription around that indication rather than weight loss alone can sometimes bypass step therapy and lifestyle program requirements. ¹¹

If Anthem Denies Your Prescription

You have a legal right to appeal. The denial letter will cite a reason code, usually prior authorization not met, step therapy, a BMI threshold, or an outright plan exclusion for weight loss drugs.

Level 1 internal appeal: file within 180 days of the denial. CarelonRx typically responds within 30 days, or 72 hours for expedited requests.
Level 2 internal appeal: file within 60 days of the Level 1 denial. You can request a peer-to-peer review, where your prescribing doctor speaks directly with an Anthem medical director.
External review: if both internal appeals fail, request an independent third-party review through your state insurance commissioner within four months of the final internal denial. This right is guaranteed under the Affordable Care Act for most health plans.

The most important document is a letter of medical necessity from the prescribing provider. It should detail your current BMI, weight history, relevant comorbidities with diagnostic codes, and evidence of prior weight loss attempts. According to the U.S. Government Accountability Office, between 39% and 59% of internal insurance appeals succeed, so a denial is not necessarily the final word. ¹¹

Paying Without Coverage

If your plan excludes weight loss drugs, retail prices are high. Wegovy carries a list price of roughly $1,350 for a 28-day supply, and Zepbound ranges from about $499 to $1,086 depending on dose and formulation. ¹²¹³

Manufacturer-direct options are cheaper. Through Eli Lilly’s LillyDirect program, Zepbound runs $299 to $449 per month depending on dose. Wegovy and Ozempic are available through NovoCare Pharmacy at $349 per month. ¹¹¹²¹³

Low-income and uninsured patients may qualify for manufacturer patient assistance programs. Novo Nordisk’s program sets the income threshold at or below 200% of the federal poverty level, and Eli Lilly’s Lilly Cares program at 300%. Both often require a Medicaid denial letter as proof that other options have been exhausted. ¹¹ Health savings accounts and flexible spending accounts can also pay the cost with pre-tax dollars, cutting the effective price by 20% to 35% depending on your tax bracket.

1
Anthem Provider News. Glucagon-Like Peptide-1 Prior Authorization Changes
2
Word & Brown. Weight Loss Drugs (GLP-1) Coverage
3
CarelonRx. Weight Management Whole Health
4
Anthem Providers. GLP-1 Coverage Considerations
5
Anthem Providers. Prior Authorization Form: Weight-Loss Management
6
Virginia DMAS. Upcoming Changes to Service Authorization Criteria for Weight Loss Drugs
7
Anthem Provider News. Glucagon-Like Peptide-1 Prior Authorization Changes
8
CMS. Medicare GLP-1 Bridge
9
CMS. Medicare GLP-1 Bridge – Information for Providers
10
CMS. BALANCE Model
11
U.S. News & World Report. How to Pay for GLP-1 Without Insurance
12
GoodRx. Wegovy for Weight Loss Cost and Coverage
13
GoodRx. Zepbound Weight Loss Tirzepatide Cost